Makarem Nader, Mourad Ahmad, Nassar Farah J, Nasr Rihab
J Med Liban. 2016 Aug;64(2):116-122.
A large family of small 18-25 nucleotide long non coding RNA molecules now known as microRNA (miRNA) was described two decades ago, and has been recently es- tablished as post-transcriptional gene regulators. miRNAs were shown to be involved in the regulation of diverse phys- iological and developmental processes. Moreover, dysregula- tion of specific miRNAs has been implicated later in several pathologies including cancer. Owing to their presence and stability in body fluids, miRNAs have been investigated as novel circulating non-invasive biomarkers. Accordingly, their role as potential diagnostic, prognostic or predictive biomark- ers for many cancer types has recently emerged. This review tackles the use of circulating miRNAs in cancer detection, diagnosis and prognosis, giving examples using common solid tumors and discussing the advantages of their use, the challenges facing this novel circulating biomarker and recorn- mendatidns to overcome them.
二十年前描述了一个现在被称为微小RNA(miRNA)的大家族,其为长度18 - 25个核苷酸的小非编码RNA分子,最近已被确立为转录后基因调节因子。miRNA被证明参与多种生理和发育过程的调节。此外,特定miRNA的失调后来与包括癌症在内的多种病理状况有关。由于它们在体液中的存在和稳定性,miRNA已被作为新型循环非侵入性生物标志物进行研究。因此,它们作为许多癌症类型的潜在诊断、预后或预测生物标志物的作用最近已显现出来。本综述探讨了循环miRNA在癌症检测、诊断和预后中的应用,以常见实体瘤为例进行说明,并讨论了其应用的优势、这种新型循环生物标志物面临的挑战以及克服这些挑战的建议。